Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1572)	6/22/2005 3:53:33 PM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI Pharma "outperform," estimates reduced Wednesday, June 22, 2005 5:38:45 AM ET Robert W. Baird NEW YORK, June 22 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma Inc (MOGN.NAS), while reducing their estimates for the company. The target price is set to $35. In a research note published this morning, the analysts mention that revenues from the company's Aloxi drug are likely to be short of expectations in 2Q05 on account of the aggressive discounting of Zofran. MGI Pharma's growth during 2H05 is likely to be boosted by US Oncology’s contract execution, the analysts say. The EPS estimate for 2005 has been reduced from $0.54 to $0.51.